Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 21, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
"These data confirm the need for consideration of these costs when prescribing treatments, and is of considerable importance as out of pocket costs continue to rise in the US.
The chief medical officer of ProMIS Neurosciences comments on how aducanumab will help propel innovation needed to drive the next generation of therapies for Alzheimer disease.
The vice president of Medical Affairs at Adamas Pharmaceuticals discussed the context of these results and what the clinical community should take away from the data from the EASE LID 2 trial of amantadine (Gocovri).
The multiple sclerosis expert at the University of Pennsylvania detailed the gaps in treatment for progressive multiple sclerosis and some of the different mechanisms being explored.
The model may help clinicians enact preventative measures for those with migraine with aura at an early stage.